NIH-funded research R21 grant

Understanding how a toxin from Group B Streptococcus is regulated

Official title: Genetic screen to define the regulation of beta-hemolysin toxin expression in Streptococcus agalactiae

Funded at University of Kentucky · NIH-10844641 · Data updated 2026-11-12

This study is looking at how a harmful toxin made by Group B Streptococcus (GBS) works, especially in people who are more at risk of getting sick, and aims to find new ways to prevent these infections by understanding the genes that control the toxin's production.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionUniversity of Kentucky
NIH-funded
Lab location1 site (Lexington, United States)
Project startMay 19, 2023
Project endApril 30, 2026
Funding year2024
Award (this year)$229,500
NIH project number5R21AI178652-02
Project IDNIH-10844641 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are elderly individuals, immunocompromised patients, and pregnant women who may be at risk for GBS infections.

Less likely to help

Patients who are healthy adults without any risk factors for GBS infections may not receive direct benefits from this research.

What this research studies

This research investigates the regulation of a specific toxin produced by Group B Streptococcus (GBS), which can cause serious infections in vulnerable populations. By developing new culture media and utilizing advanced genetic screening techniques, the researchers aim to identify genetic factors that influence the expression of this toxin. The study employs methods such as RNA sequencing and metabolomics to explore how GBS adapts its toxin production based on environmental conditions. This work could lead to new strategies for preventing GBS infections.

Why it matters

Potential benefit: If successful, this research could lead to the development of new treatments that inhibit GBS infections, particularly in at-risk populations.

How similar studies have gone: While the specific approach of this research is novel, similar studies have shown promise in understanding bacterial toxin regulation and developing targeted therapies.

Where this research is happening

  • University of Kentucky
    Lexington, United States
    Active

Researchers

  • Principal investigator: Korotkova, Natalia — University of Kentucky
  • Study coordinator: Korotkova, Natalia

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.